Evidence map›Paper›PMID 39369475›Full record

ArticleDrug and alcohol dependence2024

Buprenorphine use among non-hospital residential programs.

Cynthia Nichols, Daniel Baslock, Margaret Lloyd Sieger

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cynthia NicholsSchool of Social Work, University of Connecticut, Hartford, CT, United States. Electronic address: Cynthia.nichols@uconn.edu.
Daniel BaslockSchool of Social Work, Virginia Commonwealth University, United States.
Margaret Lloyd SiegerDepartment of Population Health, University of Kansas School of Medicine, United States.

Funding

BEHAVIORAL SCI TRAINING IN DRUG ABUSE RESEARCHT32DA007233 · NIDA · PUBLIC HEALTH SOLUTIONS · PI GOLDSAMT, LLOYD A · 1985 to 2023
$20.2M
Public Policy & Health for Substance Exposed Infant-Mother DyadsK01DA058060 · NIDA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Margaret Lloyd Sieger · 2023 to 2026
$702k
NIDA NIH HHS K01 DA058060NIDA NIH HHS T32 DA007233
6 · The paper itself

Abstract

backgroundThe purpose of this study is to investigate the use of buprenorphine within non-hospital residential programs. We hypothesize that programs offering long-term treatment will be less likely to accept or prescribe buprenorphine, but those that accept public insurance will demonstrate relative increased likelihood of buprenorphine availability.

methodThis study analyzed data from the 2021 National Substance Use and Mental Health Services Survey. The analytic sample (n=3654) included a subset of facilities that reported providing only substance use treatment, including three non-mutually exclusive service types: detox, short-term, and long-term. A logistic regression examined the association between buprenorphine availability and residential service type, holding constant characteristics associated with the outcome of interest. We then tested an interaction between public insurance and long-term service type on the outcome of interest.

resultsWhile long-term service type was associated with reduced odds of buprenorphine availability (OR=.288, p <.05), programs that both offered long-term residential programs and accepted public health insurance had 3.5 higher odds of accepting or prescribing buprenorphine (OR=4.586, p<.01) compared to long-term programs without public insurance. IMPLICATIONS: Patients who require treatment of longer duration may face barriers to buprenorphine availability; however, public insurance acceptance may increase odds of availability of buprenorphine among long-term programs.

Indexed as

BuprenorphineOpiate Substitution TreatmentOpioid-Related DisordersAdultFemaleHumansMaleMiddle AgedNarcotic AntagonistsResidential TreatmentUnited StatesBuprenorphineNarcotic AntagonistsMedications for opioid use disorderOpioid use disorderResidential treatment

Identifiers

PMID39369475
PMCPMC11527563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.